Ardena has completed the process of divesting its active pharmaceutical ingredient (API) site in Södertälje, Sweden, to Nanologica AB. Historically, the facility is well established as a drug substance CDMO with a strong track record in small-molecule APIs. Customary closing conditions have been satisfied to complete the transaction. As a specialist CDMO and bioanalytical CRO, Ardena said it will continue supporting customers with its integrated development approach. Prior to the deal, Ardena...